Related Experiment Video
Updated: May 15, 2026
11:24
Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
Published on: October 18, 2011
Long-Term Outcomes and Symptom Response Following Hypofractionated Stereotactic Radiotherapy for Intracranial
Ryan Shah1, Nilanjan Haldar2, Shray Jain3
1Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
World Neurosurgery
|May 13, 2026
Summary
Stereotactic radiosurgery (SRS) effectively controls benign meningiomas, showing high local control rates and minimal toxicity. This treatment offers a safe and effective option for patients with these brain tumors.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Benign meningiomas are common primary brain tumors.
- Various radiation dosing regimens exist for meningioma treatment.
- Patient preference and tumor characteristics influence treatment selection.
Purpose of the Study:
- To evaluate the long-term outcomes of benign meningiomas treated with hypofractionated stereotactic radiosurgery (hSRT).
- To assess local control, symptom response, and toxicity in patients receiving hSRT.
- To identify factors influencing treatment outcomes in benign meningiomas.
Main Methods:
- Retrospective review of patients with benign meningiomas treated with hSRT (25 Gy in 5 fractions).
- Collection of clinical data, including demographics, tumor characteristics, and prior treatments.
- Kaplan-Meier analysis for local control and evaluation of acute/late toxicities.
Main Results:
- 92 patients were analyzed with a median follow-up of 28 months.
- 1, 3, and 5-year local control rates were 98%, 93%, and 87%, respectively.
- 58% of patients experienced symptom improvement; 18% had G1/G2 toxicities, including 3 with radionecrosis.
Conclusions:
- Hypofractionated stereotactic radiosurgery (25 Gy/5 fractions) is effective and safe for benign meningiomas.
- High local control rates and manageable toxicity were observed.
- Further research is needed to fully understand WHO grade 1 meningiomas.
